Investors & Media

Cytokinetics In The News

Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.

Oct
11
2022
Myosin Inhibitor Aficamten Boosts QoL, Eases Symptoms in Obstructive HCM, Medscape
Oct
27
2022
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
Aug
08
2022
Cytokinetics Adds Decade of Trial Findings to PRO-ACT Database
Jun
16
2022
Evaluate
Cytokinetics aims to become the Vertex of cardiovascular disease
Jun
02
2022
Medscape
Myosin Activator May Benefit Data-Deprived Patients With Heart Failure and Low Blood Pressure
Mar
31
2022
TCTMD
Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE
Jan
07
2022
Fierce Biotech
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway

Cytokinetics Fact Sheets

More Resources